Object: In this report, we aimed to analyze the outcome results of our patients who underwent percutaneous trigeminal tractotomy (TR) and nucleotomy (NC) procedures, which are defined as destructive procedures targeting the descending trigeminal tractus and nucleus caudalis of the spinal trigeminal nucleus, respectively, for intractable craniofacial pain. Methods: The medical records of a total of 12 patients who underwent a total of 14 computed tomography (CT)-guided TR-NC procedures at our clinics between 2005 and 2017 were retrospectively reviewed. Results: A significant increase in patients’ performance status (p = 0.015) as well as a significant decrease in the VAS score (p < 0.001) were achieved. Grade I pain relief (VAS = 0, no pain) was established in 66.7% of the patients, whereas grade II pain relief was observed in the remaining patients. Two of the patients suffered from recurrent pain after the initial procedure. Both patients underwent a second trigeminal TR-NC procedure, and grade I pain relief was re-established. The mean VAS score at 3-month follow-up was 1.4 ± 1.1, whereas this score at 6-month follow-up was 2 ± 1.3. The trigeminal TR-NC procedure resulted in a significant decrease in patients’ VAS scores at 3- and 6-month follow-up visits compared with preoperative VAS scores (p < 0.001). Transient ataxia was noted in only one patient (8.3%) early after the procedure. Conclusions: The results presented in the current study support the efficacy of the percutaneous CT-guided trigeminal TR-NC procedure in the management of intractable facial pain in selected patients. The use of CT guidance allows direct visualization of the target area, thereby enhancing the safety and success of the procedure.

1.
Kanpolat
Y
,
Kahilogullari
G
,
Ugur
HC
,
Elhan
AH
.
Computed tomography-guided percutaneous trigeminal tractotomy-nucleotomy
.
Neurosurgery
.
2008
Jul
;
63
(
1
Suppl 1
):
ONS147
53
.
[PubMed]
1524-4040
2.
Raslan
AM
.
Percutaneous computed tomography-guided radiofrequency ablation of upper spinal cord pain pathways for cancer-related pain
.
Neurosurgery
.
2008
Mar
;
62
(
3
Suppl 1
):
226
33
.
[PubMed]
1524-4040
3.
Sjöqvist
O
.
Studies on pain conduction in the trigeminal nerve: a contribution to the surgical treatment of facial pain
.
Acta Psychiatr Neurol Scand
.
1938
;
Suppl 17
:
1
139
.0365-5598
4.
Hitchcock
E
.
Stereotactic trigeminal tractotomy
.
Ann Clin Res
.
1970
Aug
;
2
(
2
):
131
5
.
[PubMed]
0003-4762
5.
Hitchock
ER
,
Schvarcz
JR
.
Stereotaxic trigeminal tractotomy for post-herpetic facial pain
.
J Neurosurg
.
1972
Oct
;
37
(
4
):
412
7
.
[PubMed]
0022-3085
6.
Schvarcz
JR
.
Stereotactic trigeminal tractotomy
.
Confin Neurol
.
1975
;
37
(
1-3
):
73
7
.
[PubMed]
0010-5678
7.
Kanpolat
Y
,
Deda
H
,
Akyar
S
,
Cağlar
S
,
Bilgiç
S
.
CT-guided trigeminal tractotomy
.
Acta Neurochir (Wien)
.
1989
;
100
(
3-4
):
112
4
.
[PubMed]
0001-6268
8.
Thompson
EM
,
Burchiel
KJ
,
Raslan
AM
.
Percutaneous trigeminal tractotomy-nucleotomy with use of intraoperative computed tomography and general anesthesia: report of 2 cases
.
Neurosurg Focus
.
2013
Sep
;
35
(
3
):
E5
.
[PubMed]
1092-0684
9.
Kanpolat
Y
,
Savas
A
,
Ugur
HC
,
Bozkurt
M
.
The trigeminal tract and nucleus procedures in treatment of atypical facial pain
.
Surg Neurol
.
2005
;
64
Suppl 2
:
S96
100
.
[PubMed]
0090-3019
10.
Hosobuchi
Y
,
Rutkin
B
.
Descending trigeminal tractotomy. Neurophysiological approach
.
Arch Neurol
.
1971
Aug
;
25
(
2
):
115
25
.
[PubMed]
0003-9942
11.
Taren
JA
,
Kahn
EA
.
Anatomic pathways related to pain in face and neck
.
J Neurosurg
.
1962
Feb
;
19
(
2
):
116
21
.
[PubMed]
0022-3085
12.
Kanpolat
Y
,
Savas
S
,
Akyar
S
,
Cosman
E
.
Percutaneous computed tomography-guided spinal destructive procedures for pain control
.
Neurosurg.
2004
;
Q14
(
4
):
229
38
.
13.
Spiller
WG
,
Martin
E
.
The treatment of persistent pain of organic origin in the lower part of the body by division of the anterolateral column of the spinal cord
.
J Am Med Assoc
.
1912
;
58
(
20
):
1489
90
. 0002-9955
14.
Nashold
BS
 Jr
,
el-Naggar
A
,
Mawaffak Abdulhak
M
,
Ovelmen-Levitt
J
,
Cosman
E
.
Trigeminal nucleus caudalis dorsal root entry zone: a new surgical approach
.
Stereotact Funct Neurosurg
.
1992
;
59
(
1-4
):
45
51
.
[PubMed]
1011-6125
15.
Bekar
A
,
Taskapilioğlu
MO
,
Eser
P
,
Bilgin
H
.
CT-guided high-level percutaneous cervical cordotomy for intractable cancer pain
.
Turk Neurosurg
.
2017
;
27
(
1
):
133
7
.
[PubMed]
1019-5149
16.
Kanpolat
Y
,
Akyar
S
,
Cağlar
S
.
Diametral measurements of the upper spinal cord for stereotactic pain procedures: experimental and clinical study
.
Surg Neurol
.
1995
May
;
43
(
5
):
478
82
.
[PubMed]
0090-3019
17.
Teton
ZE
,
Holste
KG
,
Hardaway
FA
,
Burchiel
KJ
,
Raslan
AM
.
Pain-free survival after vagoglossopharyngeal complex sectioning with or without microvascular decompression in glossopharyngeal neuralgia
.
J Neurosurg
.
2019
Jan
;
132
(
1
):
232
8
.
[PubMed]
0022-3085
18.
Franzini
A
,
Moosa
S
,
D’Ammando
A
,
Bono
B
,
Scheitler-Ring
K
,
Ferroli
P
, et al
The neurosurgical treatment of craniofacial pain syndromes: current surgical indications and techniques
.
Neurol Sci
.
2019
May
;
40
(
S1
Suppl 1
):
159
68
.
[PubMed]
1590-1874
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.